US 12,168,049 B2
Attenuated flaviviruses
John Robert Coleman, Blauvelt, NY (US); Steffen Mueller, Great Neck, NY (US); and Ying Wang, South Setauket, NY (US)
Assigned to Codagenix Inc., Farmingdale, NY (US)
Appl. No. 16/976,220
Filed by Codagenix Inc., Farmingdale, NY (US)
PCT Filed Dec. 21, 2018, PCT No. PCT/US2018/067114
§ 371(c)(1), (2) Date Aug. 27, 2020,
PCT Pub. No. WO2019/172982, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/640,355, filed on Mar. 8, 2018.
Prior Publication US 2021/0000939 A1, Jan. 7, 2021
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/575 (2013.01); C12N 2770/24121 (2013.01); C12N 2770/24162 (2013.01)] 12 Claims
 
1. A modified Zika virus in which expression of viral proteins is reduced compared to a parent virus, wherein the reduction in expression is the result of recoding at least the envelope (E) region,
wherein recoding at least the envelope (E) region comprises reducing the codon pair bias;
wherein less than the entire of the E region is deoptimized,
wherein the modified virus has a safety factor of at least 102, wherein the safety factor is defined by the ratio of LD50/PD50, wherein the envelope (E) region is encoded by a nucleic acid having SEQ ID NO:8 or SEQ ID NO:9.